Int. J. Biosci.15(5), 587-593, November 2019
Acinetobacter baumannii is non-fermentive oxygen-consuming Gram-negative coccobacilli pathogen that has appeared as an essential bacteria responsible for hospital-acquired infections. It also has proved itself as an opportunistic pathogen and colonises, especially in those patients which were immunocompromised and were admitted in intensive care units (ICUs), orthopaedic wards, gynae wards and medical wards. The present study was designed to isolate the A.baumannii recovered from different wards of the hospital from various samples. The biochemical characterisation was done by analytical profile index for non-Enterobacteriaceae (API 20NE) system and was subjected for antimicrobial susceptibility pattern. Human clinical specimens like urine, blood, CSF, pus, sputum, HVS and other fluids were examined by the specific methods, and Kirby-Bauer disk diffusion method was adopted according to the Clinical and Laboratory Standards Institute guidelines (CLSI) for the examination of resistivity and susceptibility pattern of pathogens. A total of 150 isolates were recovered out of 912 specimens over the six months (July 2018 to December 2018) in a tertiary care hospital. A high proportion of isolates were resistant against the Ampicillin-Salbactum (69.33%), Cefepime (64.67%), Ceftriaxone (61.33%) and Ceftazidime (60%) whereas Papracillin-Tazobactam (66.67%), Tigecyclin (59.33%), Doxycyclin (56.67%) and Imipenem (55.33%) show maximum efficacy against the isolated pathogens. By adopting the standard policies for the use of antibiotics, increasing resistance of A. baumannii against different classes of drugs could be minimised.
Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. 2005. Multidrug-resistant Acinetobacter baumannii. Emerging infectious diseases 11, 22.
Akula S, Manderwad GP, Anukolu RSR, Rajkumar H. 2017. Emergence of Extensively drug-resistant Acinetobacter spp in a tertiary care centre of Hyderabad, Telangana state. Blood 2(1), 3.
Anupurba S, Sen M. 2005. Antimicrobial resistance profile of bacterial isolates from Intensive Care Unit: changing trends. The Journal of communicable diseases 37, 58-65.
Bergogne-Berezin E, Towner K. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical microbiology reviews 9, 148.
Constantiniu S, Romaniuc A, Iancu LS, Filimon R, Taraşi I. 2004. Cultural and biochemical characteristics of Acinetobacter spp. strains isolated from hospital units. The journal of preventive medicine 12, 35-42.
Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistantAcinetobacter baumannii. Journal of clinical microbiology 38, 4086-4095.
Dash M, Padhi S, Pattnaik S, Mohanty I, Misra P. 2013. Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna journal of medicine 3, 97.
Decré D. 2012. Acinetobacter baumannii et résistance aux antibiotiques: un modèle d’adaptation. Revue Francophone des Laboratoires 2012, 43-52.
Dimple R, Nupur S, Mahawal B, Ankit K, Ajay P. 2016. Speciation and antibiotic resistance pattern of Acinetobacter species in a tertiary care hospital in Uttarakhand. International Journal of Medical Research & Health Sciences 5, 89-96.
Fournier PE, Richet H, Weinstein RA. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clinical infectious diseases 42, 692-699.
Howard A, O’donoghue M, Feeney A, Sleator RD. 2012. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 3, 243-250.
Kamble R. 2015. Acinetobacter species in health care setting: Clinical significance and antimicrobial sensitivity. International Journal of Current Microbiology and Applied Sciences 4, 861-869.
Kirkgöz E, Zer Y. 2014. Clonal comparison of Acinetobacter strains isolated from intensive care patients and the intensive care unit environment. Turkish journal of medical sciences 44, 643-648.
Lone R, Shah A, Kadri S, Lone S, Faisal S. 2009. Nosocomial multi-drug-resistant Acinetobacter infections-clinical findings, risk factors and demographic characteristics. Bangladesh Journal of Medical Microbiology 3, 34-38.
Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. 2000. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clinical infectious diseases 31, 101-106.
Mcbride MJ. 2010. Shining a light on an opportunistic pathogen. Journal of bacteriology 192, 6325-6326.
Obeidat N, Jawdat F, Al-Bakri AG, Shehabi A. A. 2014. Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients’ respiratory tract sources. American journal of infection control 42, 401-404.
Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews 21, 538-582.
Rahal JJ. 2006. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical infectious diseases 43, S95-S99.
Rhinehart E, Friedman MM. 1999. Infection control in home care.Jones & Bartlett Learning.
Sieniawski K, Kaczka K, Rucińska M, Gagis L, Pomorski L. 2013. Acinetobacter baumannii nosocomial infections. Polish Journal of Surgery 85, 483-490.
Taneja N, Singh G, Singh M, Sharma M. 2011. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. The Indian journal of medical research 133, 681.
Visca P, Seifert H, Towner KJ. 2011. Acinetobacter infection–an emerging threat to human health. IUBMB life 63, 1048-1054.